Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Department of Cancer Genetics, The Royal Marsden NHS Foundation Trust, London, UK.
Genes Chromosomes Cancer. 2021 May;60(5):385-397. doi: 10.1002/gcc.22935. Epub 2021 Jan 11.
Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the management of recurrent ovarian cancer in patients with BRCA-mutations and beyond. Olaparib was the first PARP inhibitor to gain approval as maintenance therapy for patients with newly diagnosed, advanced BRCA-mutated ovarian cancer establishing a new standard of care. At the end of 2020, as a result of the SOLO1, PRIMA, and PAOLA-1 phase III trials, we are now in an era where three maintenance PARP inhibitor strategies have FDA and European Medicines Agency approval in the first-line setting. In this review, we provide an overview of the key PARP inhibitor trials that have changed clinical practice, discuss directing therapy according to biomarker status (BRCA and homologous recombination deficiency) and future strategies in ovarian cancer and other gynecological malignancies.
聚（ADP-核糖）聚合酶（PARP）抑制剂改变了 BRCA 突变及其他情况下复发性卵巢癌的治疗管理。奥拉帕利是首个获得批准用于新诊断的晚期 BRCA 突变卵巢癌患者维持治疗的 PARP 抑制剂，确立了新的治疗标准。2020 年底，SOLO1、PRIMA 和 PAOLA-1 三期临床试验的结果表明，我们现在处于一线治疗中已有三种维持性 PARP 抑制剂治疗策略获得美国食品药品监督管理局和欧洲药品管理局批准的时代。在这篇综述中，我们概述了改变临床实践的关键 PARP 抑制剂试验，讨论了根据生物标志物状态（BRCA 和同源重组缺陷）指导治疗以及卵巢癌和其他妇科恶性肿瘤的未来策略。
